Evaluation of the Performance of 18F-Fluorothymidine Positron Emission Tomography/Computed Tomography (18F-FLT-PET/CT) in Metastatic Brain Lesions.

18F-fluorothymidine positron emission tomography/computed tomography FLT PET/CT brain metastases

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
26 Jan 2019
Historique:
received: 24 12 2018
revised: 19 01 2019
accepted: 23 01 2019
entrez: 30 1 2019
pubmed: 30 1 2019
medline: 30 1 2019
Statut: epublish

Résumé

18F-fluorothymidine (18F-FLT) is a radiolabeled thymidine analog that has been reported to help monitor tumor proliferation and has been studied in primary brain tumors; however, knowledge about 18F-FLT positron emission tomography/computed tomography (PET/CT) in metastatic brain lesions is limited. The purpose of this study is to evaluate the performance of 18F-FLT-PET/CT in metastatic brain lesions. A total of 20 PET/CT examinations (33 lesions) were included in the study. Semiquantitative analysis was performed: standard uptake value (SUV) with the utilization of SUVmax, tumor-to-background ratio (T/B), SUVpeak, SUV1cm³, SUV0.5cm³, SUV50%, SUV75%, PV50% (volume × SUV50%), and PV75% (volume × SUV75%) were calculated. Sensitivity, specificity, and accuracy for each parameter were calculated. Optimal cutoff values for each parameter were obtained. Using a receiver operating characteristic (ROC) curve analysis, the optimal cutoff values of SUVmax, T/B, and SUVpeak for discriminating active from non-active lesions were found to be 0.615, 4.21, and 0.425, respectively. In an ROC curve analysis, the area under the curve (AUC) is higher for SUVmax (

Identifiants

DOI: 10.3390/diagnostics9010017 PMID: 30691084 PMC: PMC6468407
pubmed: 30691084
pii: diagnostics9010017
doi: 10.3390/diagnostics9010017
pmc: PMC6468407
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1407-12
pubmed: 12898201
J Nucl Med. 2006 Oct;47(10):1612-21
pubmed: 17015896
J Clin Oncol. 2007 Oct 20;25(30):4714-21
pubmed: 17947718
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2188-93
pubmed: 20544193
Clin Nucl Med. 2011 Aug;36(8):639-42
pubmed: 21716012
Q J Nucl Med Mol Imaging. 2012 Apr;56(2):151-62
pubmed: 22617237
Eur J Cancer. 2012 Dec;48(18):3499-513
pubmed: 22658807
J Nucl Med. 2012 Dec;53(12):1904-10
pubmed: 23077112
J Nucl Med. 2012 Dec;53(12):1911-5
pubmed: 23081994
Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):175-85
pubmed: 23229746
Clin Nucl Med. 2013 Aug;38(8):e318-23
pubmed: 23455521
Nucl Med Mol Imaging. 2010 Apr;44(1):45-54
pubmed: 24899937
PLoS One. 2014 Nov 13;9(11):e112577
pubmed: 25393009
Anticancer Res. 2015 Feb;35(2):955-9
pubmed: 25667480
J Nucl Med. 2016 Jul;57(7):1033-9
pubmed: 26966161
Breast Cancer Res Treat. 2016 Nov;160(1):51-59
pubmed: 27620882
J Nucl Med. 2017 Apr;58(4):584-589
pubmed: 27754904
Radiat Oncol. 2016 Oct 21;11(1):139
pubmed: 27769279
Neuro Oncol. 2017 Sep 1;19(9):1271-1278
pubmed: 28204572
Hell J Nucl Med. 2017 Jan-Apr;20(1):57-61
pubmed: 28426840
EJNMMI Res. 2017 Dec;7(1):45
pubmed: 28536967
Ann Nucl Med. 2017 Aug;31(7):495-505
pubmed: 28612247
BMC Cancer. 2017 Sep 15;17(1):649
pubmed: 28915798
BMC Cancer. 2017 Nov 6;17(1):713
pubmed: 29110648
Curr Med Chem. 2018;25(26):3074-3095
pubmed: 29149829
Front Oncol. 2018 Feb 22;8:18
pubmed: 29520339

Auteurs

Alexandra Nikaki (A)

Department of Clinical Physiology and Isotope, Kanta-Häme Central Hospital, 20 Ahvenistontie Str., 13530 Hameenlinna, Finland. anikaki@gmail.com.
Nuclear Medicine Department, University Hospital of Larissa, Mezourlo, 41110 Larissa, Thessaly, Greece. anikaki@gmail.com.
PET/CT Department, Hygeia Hospital, 4 Erythrou Stavrou Str., 15123 Athens, Greece. anikaki@gmail.com.

Vassilios Papadopoulos (V)

Department of Hematology, Papageorgiou General Hospital, Perifereiaki Odos N. Efkarpias, 56429 Thessaloniki, Greece. vassiliospap@gmail.com.

Varvara Valotassiou (V)

Nuclear Medicine Department, University Hospital of Larissa, Mezourlo, 41110 Larissa, Thessaly, Greece. vvalotasiou@gmail.com.

Roxani Efthymiadou (R)

PET/CT Department, Hygeia Hospital, 4 Erythrou Stavrou Str., 15123 Athens, Greece. r.efthimiadi@hygeia.gr.
Radiology Department, Hygeia Hospital, 4 Erythrou Stavrou Str., 15123 Athens, Greece. r.efthimiadi@hygeia.gr.

George Angelidis (G)

Nuclear Medicine Department, University Hospital of Larissa, Mezourlo, 41110 Larissa, Thessaly, Greece. gangel217@gmail.com.

Ioannis Tsougos (I)

Medical Physics Department, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Mezourlo, 41110 Larissa, Thessaly, Greece. tsougos@med.uth.gr.

Vassilios Prassopoulos (V)

PET/CT Department, Hygeia Hospital, 4 Erythrou Stavrou Str., 15123 Athens, Greece. VPrasopoulos@hygeia.gr.
Department of Nuclear Medicine, Hygeia Hospital-Mitera, 4 Erythrou Stavrou Str., 15123 Athens, Greece. VPrasopoulos@hygeia.gr.

Panagiotis Georgoulias (P)

Nuclear Medicine Department, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Mezourlo, 41110 Larissa, Thessaly, Greece. pgeorgoul@uth.gr.

Classifications MeSH